TraceLink expands European HQ to accommodate projected 207% EU employee growth in 2017
Extends EMEA sales team with addition of two new regional sales leaders in DACH and Southern Europe regions.
TraceLink will relocate its European headquarters to a larger, newly renovated office space in Uxbridge, UK. The move will accommodate the company’s projected 207% year-over-year increase in EU staff growth for 2017.
To help the life sciences industry meet global regulatory deadlines for pharmaceutical track and trace and accommodate its 658% growth in EMEA new sales bookings for Q1 2017, the company is expanding its overall European team by hiring 55 new EU-based employees in sales, services, marketing and administration during 2017.
As part of its recruitment drive, the company has added two regional EU sales leaders, deepening its pan-European presence to develop localised TraceLink teams dedicated to serving the life sciences industry in specific regions. Leading the DACH (Germany, Austria and Switzerland) region as TraceLink Vice President, Sales, Manfred Voglmaier, a native resident of Germany, brings over 25 years of industry experience in technology and life sciences, and comes from Systech International as the former Senior Director of EMEA Sales. Heading up Southern Europe, Renaud Delcroix has joined TraceLink as Vice President, Sales for the region, bringing strong expertise in cultivating international business development teams across industry verticals.
“By 2020, over 80% of the world’s prescription drugs will be covered by track and trace laws; a challenge that involves massive amounts of data and a complex web of supply chain partners. Expanding our presence in Europe is a natural step due to the urgent demand we’ve seen from the region for our proven solution in meeting EU Falsified Medicines Directive (FMD) requirements,” said Shabbir Dahod, president and CEO, TraceLink. “As part of our $70 million investment in 2017 into the pharmaceutical track and trace industry, we are building localised support and services for our customers who have mission-critical operations across 24 countries to best accommodate our rapid-growing global customer base.”
The development of the European team will be focused on continuing to build regional and native expertise in these areas, and expanding the 15 languages already spoken by the current TraceLink services team in EMEA. Worldwide, TraceLink expects to have nearly 400 employees by the end of 2017, a 68% year-over-year increase in global employee growth.
Later this year, TraceLink will offer general availability to its European Union (EU) hosted Life Sciences Cloud, furthering its commitment to serving its EU-based and global customers by enabling data residency in both the EU and US. By utilising TraceLink’s unique network-tenant platform approach, global customers will be able to significantly reduce the time, cost and risk of achieving regulatory compliance for global requirements, including the EU FMD, and eliminate the need to verify and certify point-to-point connections to each government system.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance